Interim analysis for post-marketing surveillance of dabrafenib and trametinib combination therapy in Japanese patients with unresectable and metastatic melanoma with BRAF V600 mutation

PURPOSE: To investigate the safety and efficacy of dabrafenib and trametinib combination therapy for BRAF V600 mutation-positive unresectable and metastatic melanoma in over 100 Japanese patients of a real-world clinical setting. PATIENTS: The surveillance period of interim post-marketing surveillan...

Descripción completa

Detalles Bibliográficos
Autores principales: Teshima, Yasutomo, Kizaki, Minako, Kurihara, Ryohei, Kano, Ryosuke, Harumiya, Miki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498495/
https://www.ncbi.nlm.nih.gov/pubmed/32699976
http://dx.doi.org/10.1007/s10147-020-01737-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498495/
https://www.ncbi.nlm.nih.gov/pubmed/32699976
http://dx.doi.org/10.1007/s10147-020-01737-3

Ejemplares similares